Epidemiology, treatment and health economics of Hepatitis C in Japan (Review)

Satoshi TERAMUKAI, Haku ISHIDA, Yuji INOUE, 日本におけるジェノタイプ1b・高ウイルス量のC型慢性肝炎に対するコンセンサス・インターフェロンの費用対効果 Japanese Journal of Pharmacoepidemiology\/yakuzai Ekigaku. ,vol. 7, pp. 1- 11 ,(2002) , 10.3820/JJPE1996.7.1

K. Yoshizawa, M. Ota, S. Saito, A. Maruyama, T. Yamaura, A. Rokuhara, K. Orii, T. Ichijo, A. Matsumoto, E. Tanaka, K. Kiyosawa, Long-term follow-up of hepatitis C virus infection: HLA class II loci influences the natural history of the disease. Tissue Antigens. ,vol. 61, pp. 159- 165 ,(2003) , 10.1034/J.1399-0039.2003.00015.X

N. Hayashi, T. Okanoue, H. Tsubouchi, J. Toyota, K. Chayama, H. Kumada, Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. Journal of Viral Hepatitis. ,vol. 19, ,(2012) , 10.1111/J.1365-2893.2011.01528.X

Yasuji Arase, Mariko Kobayashi, Fumitaka Suzuki, Yoshiyuki Suzuki, Yusuke Kawamura, Norio Akuta, Masahiro Kobayashi, Hitomi Sezaki, Satoshi Saito, Tetsuya Hosaka, Kenji Ikeda, Hiromitsu Kumada, Tetsuro Kobayashi, Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology. ,vol. 57, pp. 964- 973 ,(2013) , 10.1002/HEP.26087

Kenshi Hayashida, Ichiro Nagasue, Takashi Fukuda, Atsuaki Gunji, The natural history model of hepatitis C virus infection and the economic evaluation of alpha interferon treatment. Journal of Epidemiology. ,vol. 12, pp. 22- 32 ,(2002) , 10.2188/JEA.12.22

Hiromitsu Kumada, Joji Toyota, Takeshi Okanoue, Kazuaki Chayama, Hirohito Tsubouchi, Norio Hayashi, Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan Journal of Hepatology. ,vol. 56, pp. 78- 84 ,(2012) , 10.1016/J.JHEP.2011.07.016

Christophe Hézode, Nicole Forestier, Geoffrey Dusheiko, Peter Ferenci, Stanislas Pol, Tobias Goeser, Jean-Pierre Bronowicki, Marc Bourlière, Shahin Gharakhanian, Leif Bengtsson, Lindsay McNair, Shelley George, Tara Kieffer, Ann Kwong, Robert S. Kauffman, John Alam, Jean-Michel Pawlotsky, Stefan Zeuzem, Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. The New England Journal of Medicine. ,vol. 360, pp. 1839- 1850 ,(2009) , 10.1056/NEJMOA0807650

Y INOUE, Medical economics: Hepatitis C virus infection and cost-effectiveness of Interferon therapy Hepatology Research. ,vol. 24, pp. 57- 67 ,(2002) , 10.1016/S1386-6346(02)00041-4

Eiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, Kazuhiro Takahashi, Hideyuki Nomura, Toshihiro Maruyama, Yuichi Tanabe, Takeaki Satoh, Makoto Nakamuta, Kazuhiro Kotoh, Koichi Azuma, Kazufumi Dohmen, Shinji Shimoda, Jun Hayashi, Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: A prospective, multicenter study Journal of Hepatology. ,vol. 58, pp. 495- 501 ,(2013) , 10.1016/J.JHEP.2012.10.017

Hisayuki Hamada, Hiroshi Yatsuhashi, Koji Yano, Manabu Daikoku, Kokichi Arisawa, Osami Inoue, Michiaki Koga, Keisuke Nakata, Katsumi Eguchi, Michitami Yano, Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C Cancer. ,vol. 95, pp. 331- 339 ,(2002) , 10.1002/CNCR.10662